

## SLC26A2 RELATED DIASTROPHIC DYSPLASIA IN 42-YEARS UKRAINIAN WOMEN

Bondarenko M.<sup>1</sup>, Haiboniuk I.<sup>2,3</sup>, Solovei I.<sup>4</sup>, Shargorodska Y.<sup>2</sup>, Makukh H.<sup>2,3\*</sup>

\***Corresponding Author:** Makukh Halyna, Ph.D., 31-A Lysenko Institute of Hereditary Pathology of the Ukrainian National Academy of Medical Sciences, Lviv, Ukraine, & Scientific Medical Genetic Center LeoGENE, Maksymovych, 7g str, Lviv, Ukraine, 79059. Tel +380677191380, E-mail: mgdc@leogene.com.ua

### ABSTRACT

Diastrophic dysplasia (DTD) is an uncommon pathology which falls under the group of skeletal dysplasias with its first symptoms observed from birth. The pathology is often featured by short stature and abnormally short extremities (also known as short-limbed dwarfism); the osseous structures of the body (bones and joints) are characterized through defective development in many body regions. More than 300 genes were reported to be involved in DTD etiology with autosomal recessive, autosomal dominant and X-linked manner.

We describe clinical case of a 42-year-old woman from the west of Ukraine with diastrophic dysplasia and two pathogenic variants *c.1020\_1022del (p.Val341del)* and *c.1957T>A (p.Cys653Ser)* identified in *SLC26A2* gene.

SLC26A2-related diastrophic dysplasia was confirmed based on the presence of pathogenic variants in *SLC26A2*, which is associated with autosomal recessive forms of skeletal dysplasia, combined with phenotypic symptoms and radiographic findings.

**Keywords:** Diastrophic Dysplasia, *SLC26A2*, mutation, Ukraine.

### INTRODUCTION

Diastrophic dysplasia (DTD), or diastrophic dwarfism, is an uncommon genetic pathology falling under the group of skeletal dysplasias [1]. It is a progressive condition conducting to physical disability [2]. The first signs of DTD are observed at birth and develop following the defects in cartilage buildup process, affecting skeletal formation. Additionally, respiratory complications may lead to increased mortality in children with DTD in the neonatal period [3]. The associated symptomatic findings include their severity and range, showing a wide diversity in separate cases. Concurrently, the clinical features often include limb shortening (short-limbed dwarfism) and short stature; defective development of joints (joint dysplasia) and bone structure (skeletal dysplasia) in many body regions; progressive pathological spine curvature (predominantly scoliosis and/or kyphosis); pathological changes in the pinnae tissue (external ear parts); they may also include craniofacial area malformations [4, 9, 11, 21]. IQ is usually normal.

The diagnosis is based on the presence of pathogenic variants in *SLC26A2*, which is associated with autosomal recessive forms of skeletal dysplasia, in pair with phenotypic symptoms and radiographic findings [5]. Confirmation of diagnosis during the prenatal period can be executed by ultrasound and an invasive prenatal diagnostic with a molecular genetic testing [6].

More than 300 genes were reported to be involved in skeletal dysplasia with autosomal recessive (AR), autosomal dominant and X-linked manner (Table 1). Clinical signs of all these diseases have similar manifestations and a comparable phenotype, thus only genetic testing results can state the appropriate diagnosis and determine the disorder risk for relatives. The type of inheritance and

<sup>1</sup> Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.

<sup>2</sup> Institute of Hereditary Pathology of the Ukrainian National Academy of Medical Sciences, Lviv, Ukraine.

<sup>3</sup> Scientific Medical Genetic Center LeoGENE, LTD, Lviv, Ukraine.

<sup>4</sup> D. Halytskii L'viv National Medical University, Lviv, Ukraine.

**Table 1.** The type of inheritance and genes associated with different forms of skeletal dysplasia

<b>Group or name of the disorder</b>	<b>Mode of Inheritance</b>	<b>Gene Symbol</b>
<b>FGFR3 disorders</b>		
Thanatophoric dysplasia	AD	<i>FGFR3</i>
Achondroplasia	AD	<i>FGFR3</i>
Hypochondroplasia	AD	<i>FGFR3</i>
SADDNA	AD	<i>FGFR3</i>
<b>Type II collagen disorders</b>		
Achondrogenesis II	AD	<i>COL2A1</i>
Hypochondrogenesis	AD	<i>COL2A1</i>
Spondyloepiphyseal dysplasia congenita (SEDC)	AD	<i>COL2A1</i>
Kniest dysplasia	AD	<i>COL2A1</i>
<b>Type X1 collagen disorders</b>		
Fibrochondrogenesis	AR	<i>COL11A1</i>
Fibrochondrogenesis	AD	<i>COL11A1, COL11A2</i>
Otospondylomegaepiphyseal dysplasia (OSMED)	AR	<i>COL11A2</i>
<b>Sulfation disorders</b>		
Achondrogenesis IB	AR	<i>SLC26A2</i>
Atelosteogenesis II	AR	<i>SLC26A2</i>
Diastrophic dysplasia	AR	<i>SLC26A2</i>
Chondrodysplasia with congenital joint dislocations	AR	<i>CHST3</i>
<b>Perlecan disorders</b>		
Dyssegmental dysplasia	AR	<i>PLC</i>
Dyssegmental dysplasia, Silverman-Handmaker type	AR	<i>PLC</i>
Dyssegmental dysplasia, Rolland Desbuquois type	AR	<i>PLC</i>
<b>Filamin Disorders and similar disorders</b>		
Otopalatodigital syndrome I and II	XLD	<i>FLNA</i>
Osteodysplasty, Melnick-Needles	XLD	<i>FLNA</i>
Atelosteogenesis types I and III	AD	<i>FLNB</i>
Larsen syndrome	AD	<i>FLNB</i>
Spondylo-carpal-tarsal dysplasia	AR	<i>FLNB</i>
Serpentine fibula-polycystic kidney syndrome	AD	<i>NOTCH2</i>
<b>TRPV4 disorders</b>		
Metatopic dysplasia	AD	<i>TRPV4</i>
<b>Short-rib dysplasias (with and without polydactyly)</b>		
Chondroectodermal dysplasia (Ellis-van Creveld (EVC))	AR	<i>EVC1, EVC2</i>
Short-rib polydactyly syndrome I, II, III and IV including Asphyxiating Thoracic Dystrophy	AR	<i>DYNC2H1, IFT80, NEK, WDR35, WDR19, WDR34</i>
Thoracolaryngeal dysplasia	AD	<i>unknown</i>
<b>Metaphyseal dysplasias</b>		
Cartilage-hair hypoplasia	AR	<i>RMRP</i>
Metaphyseal dysplasia, Jansen type	AD	<i>PTHR1</i>
<b>Spondylo-epi-(meta)-physeal dysplasia</b>		
SEMD, short limb abnormal calcification type	AR	<i>DDR2</i>
<b>Severe spondylyodysplastic dysplasias</b>		
Achondrogenesis 1A	AR	<i>GMAP210</i>
Schneckenbecken dysplasia	AR	<i>SLC35D1</i>
Opsismodysplasia	AR	<i>INPPL1</i>
<b>Acromesomelic disorders</b>		
Acromesomelic dysplasia, type Maroteaux	AR	<i>NPR2</i>

Continues on the next page

Continuation of the previous page

<b>Mesomelic and rhizo-mesomelic dysplasias</b>		
Langer type (homozygous dyschondrosteosis)	pseudo-AR/XLD	<i>SHOX</i>
Omodysplasia	AR	<i>GPC6</i>
Robinow syndrome, recessive	AR	<i>ROR2</i>
Robinow syndrome, dominant	AD	<i>WNT5</i>
<b>Bent bone dysplasias</b>		
Campomelic dysplasia	AD	<i>SOX9</i>
Stuve-Wiedemann dysplasia	AR	<i>LIFR</i>
Bent bone dysplasia FGFR2 type	AD	<i>FGFR2</i>
<b>Slender bone dysplasias</b>		
Microcephalic osteodysplastic primordial dwarfism (MOPD1)	AR	<i>RNU4ATAC</i>
Microcephalic osteodysplastic primordial dwarfism (MOPD2)	AR	<i>PCNT</i>
Osteocraniostenosis		<i>FAM111A</i>
<b>Dysplasias with multiple joint dislocations</b>		
Desbuquois dysplasia	AR	<i>CANT1, XYLT1</i>
Pseudodiaphyseal dysplasia	AR	<i>unknown</i>
<b>Chondrodysplasia punctata group (CDP)</b>		
CDP, X-linked dominant	XLD	<i>EBP</i>
Conradi-Hunermann type (CDPX2)	XLR	<i>ARSE</i>
brachytelephalangic type (CDPX1)	XLD	<i>NSDHL</i>
CHILD syndrome	XLD	<i>EBP</i>
Greenberg dysplasia	AR	<i>LBR</i>
Rhizomelic CDP type 1	AR	<i>PEX7</i>
Rhizomelic CDP type 2	AR	<i>DHPAT</i>
Rhizomelic CDP type 3	AR	<i>AGPS</i>
<b>Neonatal osteosclerotic dysplasias</b>		
Bloomstrand dysplasia	AR	<i>PTHR1</i>
Desmoterolosis	AR	<i>DHCR24</i>
Caffey disease (infantile)	AD	<i>COL1A1</i>
Raine dysplasia	AR	<i>FAM20C</i>
<b>Increased bone density group</b>		
Osteopetrosis (severe neonatal or infantile forms)	AR	<i>TCIRG1</i>
Osteopetrosis (severe neonatal or infantile forms)	AR	<i>CLCN7</i>
Dysosteosclerosis	AR	<i>SLC29A3</i>
Lenz-Majewski hyperostotic dysplasia	SP	<i>PTDSS1</i>
<b>Osteogenesis imperfecta and decreased bone density group</b>		
Osteogenesis imperfecta, moderate, severe and perinatal lethal	AD	<i>COL1A1, COL1A2, IFITM5</i>
Osteogenesis imperfecta, moderate, severe and perinatal lethal	AR	<i>CRTAP, P3H1, PP1, FKBP10, HSP47, SP7, WNT1, TMEM33B</i>
Bruck syndrome		<i>PLOD2, FKBP10</i>
Osteoporosis-pseudoglioma syndrome	AR	<i>LRP5</i>
Cole-Carpenter dysplasia	SP	<i>unknown</i>
<b>Abnormal mineralization group</b>		
Hypophosphatasia, perinatal and infantile forms	AR	<i>ALPL</i>

AD – autosomal dominant type, AR- autosomal recessive, XLD- X-linked dominant, XLR- X-linked recessive, SP- supertype

genes associated with different forms of skeletal dysplasia are presented in the Table 1. The prevalent skeletal dysplasia type is *FGFR3*-related disorders, inherited in an autosomal-dominant manner [6].

Diastrophic dysplasia occurs predominantly among the Caucasian population [3, 8]. The prevalence of DTD is estimated at 1-1.3/100,000, and mainly has an AR type of inheritance. The disorder affects both males and females in equal numbers [4]. This pathology is widespread in Finland, occurring in about 1 in 30,000 newborns. In particular, 1-2% of the Finnish population are carriers of pathogenic variants of the *SLC26A2* gene [14]. Mutations in this gene demonstrate a very diverse clinical spectrum. 183 cases of DTD have been diagnosed and described in Finland.

Frequency of occurrence of this disorder in our country is unknown. Several cases of *FGFR3*-related condition have been reported among Ukrainian patients, but there are no reliable data on the prevalence of skeletal dystrophy with other types of inheritance. We present this case report of DTD in a 42-year-old Ukrainian woman, whose DTD is caused by *SLC26A2* gene biallelic pathogenic variants.

Mutation in the *SLC26A2* gene (otherwise known as the Diastrophic Dysplasia Sulfate Transporter (*DDST*) gene) is to be found on the long arm of chromosome 5 (5q32-q33.1) [<https://www.genecards.org/cgi-bin/card-disp.pl?gene=SLC26A2>] and leads to the occurrence of diastrophic dysplasia and other skeletal dysplasias with a diverse clinical gravity. The *SLC26A2* gene is responsible for protein that transports sulfate ions across cell membranes, being necessary for the formation of proteoglycans. Proteoglycans help provide cartilage with its consistency. Since sulfate ion particles are necessary for the formation of proteoglycans, the activity of the *SLC26A2* protein is fundamental for cartilage development [7, 12].


*SLC26A2* gene mutations that cause diastrophic dysplasia (described more than 20 mutations [7, 8]) lead to a deficiency of sulfate ions. Therefore, the normal formation of cartilage and bone growth are disturbed [13, 14, 16]. The most frequently occurring variants are *p.Arg279Trp* (ratio in the disease alleles is 37%), *p.Arg178Ter*, *c.-26+2T>C* and *p.Cys653Ser* (13, 8 and 6%, respectively). Other pathogenic variants are at  $\leq 3\%$  each. Compound heterozygous pathogenic variants are reported in most cases of DTD (97%) [17, 18].

Taking into the account the rareness of the disease, ethnic difference, and the lack of reporting about DTD disease course in adults, we present the phenotype description of 42-year-old woman from the west of Ukraine with diastrophic dysplasia and two pathogenic variants in the *SLC26A2* gene.

**CASE REPORT**

We present a case of DTD in a 42-year-old Ukrainian woman. The patient's stature is 110 cm with S-shaped deformation of the spine. The patient's daughter applied to the Medical Genetic Center for advice on pregnancy planning and the possible risk of skeletal dysplasia for future children. The daughter is clinically healthy.

The anamnesis and result of examination of her mother with skeletal dysplasia is as follows: she has been patient from a physiological birth. Her birth weight was 4,200 kg. After birth, the newborn was diagnosed with severe asphyxia. The parents of the woman are somatically healthy, and they are not closely related. No cases of skeletal dysplasia in the family have been reported. The patient also had stridor nasal breathing at birth. The phenotype of the patient had the following features: the lower extremities were poorly stretched and tight to the body. The conclusion of the orthopedist during the examination was that the shortening of long (tubular) bones were manifested more on the lower extremities. At the age of 1 year the diagnosis was congenital dislocation of a hip, bilateral; arthrogryposis. At age of 21, she was diagnosed with a mixed form of chronic cholecystitis. At the age of 23, she was diagnosed with left ureter contraction, urolithiasis, chronic gastritis, kyphoscoliosis. At the age of 24, she was diagnosed with spondyloepiphyseal dysplasia, obsolete injury of the left shoulder. The woman was referred for consultation to the Institute of Traumatology and Orthopedics, where she was



**Figure 1.** MRI findings of DD patient: Scoliosis (4<sup>th</sup> grade), osteochondrosis, spondyloarthrosis of the spine. Protrusions of disks C3-C4, C4-C5, C5-C6, C6-C7, L5-S1



diagnosed with multiple skeletal bone deformities. They recommended to perform an MRI to assess skeletal bone damage. The MRI findings showed scoliosis (4<sup>th</sup> grade), osteochondrosis, spondyloarthritis of the spine. There were also protrusions of disks C3-C4, C4-C5, C5-C6, C6-C7, and L5-S1 (Figure 1). Intervertebral space contracted from L1 to L5 (Figure 1).

The patient has the skull of normal size with a disproportionately short skeleton, short lower extremities, brachydactylia, lack of interphalangeal creases, and hitch-

In *LTBP2* gene, a Variant of Uncertain Significance, or *c.3913G>C (p.Asp1305His)*, was identified.

The *LTBP2* gene is related to microspherophakia and autosomal recessive primary congenital glaucoma (PCG). The *LTBP2* gene also shows preliminary evidence asserting association with autosomal recessive Marfan-like syndrome and autosomal recessive type 3 Weill-Marchesani syndrome (WMS). In the *TTC21B* gene, a Variant of Uncertain Significance, *c.3932G>A (p.Arg1311His)*, was identified. The *TTC21B* gene correlates with asphyxiat-



Figure 2



Figure 3




Figure 4

**Figure 2, 3, 4.** The phenotypic traits of DD patient: brachydactylia (short fingers), absence of flexion creases of the fingers, and proximally placed, abducted «hitchhiker thumb».

hiker thumb (abducted, located proximally) (Figures 2, 3, 4). The patient also has a vision defect, specifically myopia. Deviations in intellectual development were not observed. She has two healthy children born by caesarean section.

Due to the observed phenotype and skeletal deformities, the genetic testing of the panel genes involved in the etiology of skeletal disorders was performed by the next generation sequencing (NGS) method. The selected diagnostic test evaluates complete sequencing and deletion/duplication of 320 genes (Appendix 1) for variants, which are associated with genetic disorders that have phenotype of skeletal dysplasia. Two pathogenic variants in the *SLC26A2* gene and two variants with uncertain value were revealed in the patient. The *SLC26A2* gene mutations *c.1020\_1022del (p.Val341del)* and *c.1957T>A (p.Cys653Ser)* were confirmed.

ing thoracic dystrophy and autosomal recessive nephrophtosis. (Table 2)

Two pathogenic variants, *c.1020\_1022del (p.Val341del)* and *c.1957T>A (p.Cys653Ser)*, were identified in *SLC26A2*, and the diagnosis of diastrophic dysplasia was confirmed. This condition has an autosomal-recessive manner of inheritance. Two descendants of the patient had normal phenotypes and both were heterozygous carriers of the mutation. *SLC26A2* mutation testing for future partners was recommended during the medical-genetic consultation.

## DISCUSSION

Skeletal dysplasias belong to a genetically heterogeneous group of dysplasias, which may be caused by different mutations in more than 300 genes [19]. The main

**Table 2.** The identified in DD patient gene variants.

GENE	VARIANT	ZYGOSITY	VARIANT CLASSIFICATION
SLC26A2	<i>c.1020_1022del (p.Val341del)</i>	heterozygous	PATHOGENIC
SLC26A2	<i>c.1957T&gt;A (p.Cys653Ser)</i>	heterozygous	PATHOGENIC
LTBP2	<i>c.3913G&gt;C (p.Asp1305His)</i>	heterozygous	Uncertain Significance
TTC21B	<i>c.3932G&gt;A (p.Arg1311His)</i>	heterozygous	Uncertain Significance

phenotypic presentation for those are growth disorders. The diagnosis of diastrophic dysplasia implies the conjunction of clinical, radiological, and histopathological symptoms. Establishing an accurate diagnosis is a complicated task, and the results of genetic testing play a key role here.

In the presented case, the 42-year-old woman was found to have *SLC26A2* mutations *1020\_1022del* (*p.Val341del*) and *c.1957T> A* (*p.Cys653Ser*). The *SLC26A2 c.1957T> A* (*p.Cys653Ser*) pathogenic variant is the third prevalent one among the described in DTD patients. The *SLC26A2* gene is considered to be related to autosomal recessive achondrogenesis, type IB (*ACG1B*), atelosteogenesis type 2 (AO2), diastrophic dysplasia (DTD), and multiple epiphyseal dysplasia 4 (EDM4). If two causative variants are present on opposite chromosomes, then it is consistent with a diagnosis of *SLC26A2*-related conditions. *SLC26A2*-related conditions fall under the spectrum of skeletal dysplasias demonstrating a variable manifestation rate. *ACG1B* and *AO2* (also known as De la Chapelle dysplasia) involve significant shortening of extremities and compromised skeletal ossification, and these are typically lethal in the perinatal period. DTD can be lethal in infancy; *EDM4* is the mildest *SLC26A2*-associated disorder and is characterized by clubfoot, double-layered patellae, flat epiphyses, mild feet and hands deformations, and joint pain. This condition causes recessive multiple epiphyseal dysplasia (rMED) in the presence of homozygous carrier or rMED and DTD when in combination with other morbigenous variants [17].

The parents of the patient are not available to identify the trans- or cis- position of two pathogenic variants on the chromosome. Two healthy descendants of our proband are healthy heterozygous carriers, confirming the location of the *SLC26A2* variants on different chromosomes. We have seen no evidence of an excessive probability of degenerative joint disease. We have advised on examination of their partners in future to prevent the DTD in offspring.

Nutritional counseling to prevent obesity is important for such patients, as well as a multidisciplinary approach to their management [15, 16].

Future study shows the need to clarify the significance of different types of DTD among patients of Ukrainian origin with skeletal dysplasia symptoms and to estimate heterozygous carrier rates in the population. The results of the genetic testing and evaluating of the DTD-involved gene could be important for the selection of management and new treatment development.

**REFERENCES**

1. Dwyer E, Hyland J, Modaff P, Pauli RM. Genotype-phenotype correlation in DTDST dysplasias: Atelosteogenesis type II and diastrophic dysplasia variant in one family. *Am J Med Genet A*. 2010; 152 a (12):3043-50.
2. Szczepaniak-Kubat A, Tesiorowski M, Merc-Gołebiewska Z, Jakubowska-Pietkiewicz E. Diastrophic dysplasia in a seven-year-old girl. Case study. *Ortop Traumatol Rehabil*. 2010 May-Jun;12(3):257-63
3. Pineda T, Rossi A, Bonafè L, Superti-Furga A, Velasco Harv M. Report of a novel mutation in the *SLC26A2* gene found in a Colombian adult patient with diastrophic dysplasia. *Revista de la Facultad de Medicina*. 2013; 61(3): 255-259.
4. Diastrophic Dysplasia. In: Adam MP, Ardinger HH, Pagon RA, et al., University of Washington, Seattle; 2013: 1993-2021.
5. Farooq Ahamdb, Muhammad Bilalb, Abdulaziz Asiria, Muhammad Younusc, Amjad Khand. A Comprehensive review of genetic skeletal disorders reported from Pakistan: A brief commentary. *Meta Gene*. 2019; 2: 100559.
6. Honório J ; Bruns R, Gründtner L, Raskin S, Ferrari L, Júnior E, Nardoza L, Diastrophic dysplasia: Prenatal diagnosis and review of the literature. *Sao Paulo Med. J*. 2013, 131, 127–132.
7. Zheng C. Lin X. Xu X. Wang C. Zhou J. Gao B. et al. Suppressing UPR-dependent overactivation of FGFR3 signaling ameliorates *SLC26A2*-deficient chondrodysplasias. *EBioMedicine* 2019; 40: 695–709.
8. Hästbacka J, Kerrebrock A, Mekkala K, Clines G, Lovett M, Kaitila I et al. Identification of the Finnish founder mutation for diastrophic dysplasia (DTD). *Eur J Hum Genet*. 1999; 7: 664-670.
9. Rossi A, Superti-Furga A. Mutations in the diastrophic dysplasia sulfate transporter (DTDST) gene (*SLC26A2*): 22 novel mutations, mutation review, associated skeletal phenotypes, and diagnostic relevance. *Hum Mutat*. 2001; 17:159–71.
10. Mehran Kausar, Riikka E Mäkitie, Sanna Toiviainen-Salo, Jaakko Ignatius, Mariam Anees, Outi Mäkitie Recessive multiple epiphyseal dysplasia - Clinical characteristics caused by rare compound heterozygous *SLC26A2* genotypes. *Eur J Med Genet*. 2019; 62(11): 103573.

11. Bieganski T, Faflik J, Kozlowski K. Diastrophic dysplasia with severe primary kyphosis and ‘monkey wrench’ appearance of the femora. *Australas Radiol.* 2000; 44: 450-53.
12. Czarny-Ratajczak M, Bieganski T, Rogala P, Glowacki M, Trzeciak T, Kozlowski K. New intermediate phenotype between MED and DD caused by compound heterozygous mutations in the *DTDST* gene. *Am J Med Genet Part A.* 2010; 152(A): 3036–3042.
13. Krista A. Geisterl, Sally A. *Advances in Skeletal Dysplasia Genetics. Annual Review of Genomics and Human Genetics*, 2015; 16: 199-227.
14. Härkönen, H.; Loid, P.; Mäkitie, O. *SLC26A2-Associated Diastrophic Dysplasia and rMED—Clinical Features in Affected Finnish Children and Review of the Literature. Genes.* 2021; 12: 714.
15. Paganini C. Tota C.G. Monti L. Monti I. Maurizi A. Capulli M. et al. Improvement of the skeletal phenotype in a mouse model of diastrophic dysplasia after postnatal treatment with N-acetylcysteine. *Biochem. Pharmacol.* 2021; 185: 114452.
16. Saari A. Sankilampi U. Hannila M.-L. Kiviniemi V. Kesseli K. Dunkel L. New Finnish growth references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-length/height, and body mass index-for-age. *Ann. Med.* 2010; 43: 235–248.
17. Kausar M. Mäkitie R.E. Toiviainen-Salo S. Ignatius J. Anees M. Mäkitie O. Recessive multiple epiphyseal dysplasia—Clinical characteristics caused by rare compound heterozygous *SLC26A2* genotypes. *Eur. J. Med. Genet.* 2019; 62: 103573.
18. Syvänen J. Helenius I. Hero M. Mäkitie O. Ignatius J. Recessive MED with auricular swelling due to compound heterozygosity Arg279Tpr/Thr512Lys in the *SLC26A2* gene. *Am. J. Med. Genet. Part A.* 2013; 161: 1491–1494.
19. Superti-Furga A, Unger S, and the Nosology Group of the International Skeletal Dysplasia Society. Nosology and classification of genetic skeletal disorders: *Am J Med Genet. Part A.* 2007; 143A: 1–18.
20. Buyse ML. *Birth Defects Encyclopedia.* Dover, MA: Blackwell Scientific Publications, Inc. 1990: 533-35.
21. Superti-Furga A. Skeletal dysplasias related to defects in sulfate metabolism. In: Royce P, Steinmann B, editors. *Connective Tissue and its heritable disorders*, 2 Ed. New York: Wiley-Liss, Inc. 2002. 939-60.